Technology Available for Industry-Academia Collaboration or Technology Licensing. “Characterizing molecular and clinical features in hepatopancreatobiliary cancers”
Date: 2026.07.13
- Title:
NHRI technology, “Characterizing molecular and clinical features in hepatopancreatobiliary cancers” available for industry-academia collaboration or technology licensing.
- Description:
Previous studies have indicated that hepatopancreatobiliary cancers patients with different mutations tend to have different overall survival (OS), with each mutation subgroup potentially exhibiting slight different OS. However, the progression-free survival (PFS) for first-line and second-line treatments remains poorly characterized in hepatopancreatobiliary cancers. Furthermore, some patients are willing to receive treatment but maybe not suitable for intravenous chemotherapy. The OS for supportive care only is also important for designing a first-line trial focused on chemotherapy-ineligible patients. As some mutations are increasingly recognized as a potential druggable target, establishing benchmarks for first-line and second-line PFS—which is the FDA-endorsed surrogate endpoint for accelerated approval in phase II trials—is crucial. Therefore, the aim of this study is to describe the molecular and clinical features of hepatopancreatobiliary cancers through an international collaborative medical record review study.
- Potential collaboration partner qualifications:
- be incorporated and approved by law and does not have any record of misconduct or conviction for any offense
- better to have related experience and skills for developing The Technology.
- Registration：
Please contact to Ms. Wen-Chuan Hsieh (email: wenchuan@nhri.edu.tw). Address: Technology Transfer and Incubation Center, National Health Research Institutes, 35 Keyan Road, Zhunan Town, Miaoli County 35053, Taiwan.
- Other:
- NHRI retains the right to modify and terminate this announcement.
- For detailed status of The Technology, please contact to the case officer.
